Agios CSO to de­part amid lay­offs as biotech looks for new drugs to li­cense or ac­quire

A year and a half af­ter end­ing work in on­col­o­gy and three months af­ter se­cur­ing the first nod for its new “an­chor prod­uct,” Agios is once again shak­ing things up.

As many as 50 ex­plorato­ry re­search em­ploy­ees will be let go and chief sci­en­tif­ic of­fi­cer Bruce Car will de­part the com­pa­ny at the end of Ju­ly, the biotech said af­ter the clos­ing bell Mon­day. That rep­re­sents near­ly 13% of the work­force that Agios em­ployed at the end of 2021, with 390 full-time work­ers as of De­cem­ber 31.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER